UroGen Pharma Ltd. — Director's Dealing 2022

Feb 2, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2022-01-31

Reporting Person: Barrett Elizabeth A. (Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-01-31	Ordinary Shares	M	5000	—	Acquired	303220	Direct
2022-01-31	Ordinary Shares	S	2235	$7.58	Disposed	300985	Direct
2022-01-31	Ordinary Shares	M	13333	—	Acquired	314318	Direct
2022-01-31	Ordinary Shares	S	5960	$7.58	Disposed	308358	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-01-31	Restricted Stock Units	$	M	5000	Disposed		Ordinary Shares (5000)	Direct
2022-01-31	Restricted Stock Units	$	M	13333	Disposed		Ordinary Shares (13333)	Direct
2022-01-31	Stock Option (right to buy)	$7.72	A	150000	Acquired	2032-01-31	Ordinary Shares (150000)	Direct

Footnotes

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer

F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units

F3: The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 15,000 ordinary shares. The RSUs vest in three equal annual installments from January 31, 2021.

F4: The reporting person was granted restricted stock units ("RSUs") on January 31, 2021 representing 40,000 ordinary shares. The RSUs vest in three equal annual installments from January 31, 2022.

F5: 1/3 of the shares underlying the stock options will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025